Drug intelligence / Profile preview

CB CAR-NK182

Development stage: Phase 1
Lead developer: Hangzhou Ronggu Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CB CAR-NK182 is an investigational cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting Claudin18.2 (CLDN18.2). Developed by Zhejiang Provincial People's Hospital, this biologic immunotherapy involves genetically modifying NK cells harvested from umbilical cord blood to express a CAR specific for CLDN18.2, a protein frequently overexpressed in certain gastrointestinal malignancies, including gastric and pancreatic cancers. The therapy is designed to harness the innate cytotoxic potential of NK cells while providing targeted specificity against tumor cells, potentially offering a safer alternative to CAR-T cell therapies due to a reduced risk of cytokine release syndrome and graft-versus-host disease. It is currently being evaluated in a Phase I clinical trial to determine the maximum tolerated dose, safety, and preliminary efficacy in patients with advanced gastric cancer and advanced pancreatic adenocarcinoma.

Other names: Cord blood-derived CAR-NK cells targeting Claudin18.2

Targets

Claudin 18.2

Beyond the preview

Go deeper on CB CAR-NK182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB CAR-NK182.

Explore the full profile